November 2017

Apellis Pharmaceuticals Announces Closing of its Initial Public Offering

Crestwood, Kentucky, Nov. 13, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its initial public offering of 10,714,000 shares of common…

Apellis Pharmaceuticals Announces Pricing of Initial Public Offering

Crestwood, Kentucky, Nov. 08, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its initial public offering of 10,714,000 shares of…

New Study: Innovative Heart Device is Safe and Effective

Device May Improve Quality and Frequency of Repair Baltimore, Maryland – A new study has found that a pioneering device to repair heart valves is safe and effective, and can reduce the invasiveness and side effects of conventional mitral valve surgery. The Harpoon Mitral Valve…